Gena Wang
Stock Analyst at Barclays
(2.41)
# 2,418
Out of 5,174 analysts
237
Total ratings
41.77%
Success rate
-0.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $90 → $80 | $17.09 | +368.11% | 8 | Feb 4, 2026 | |
| CYTK Cytokinetics | Assumes: Overweight | $87 | $60.02 | +44.95% | 6 | Jan 28, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $81 → $50 | $18.50 | +170.27% | 7 | Nov 24, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Overweight | $38 → $33 | $9.18 | +259.48% | 3 | Nov 11, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $31 → $25 | $51.34 | -51.31% | 11 | Nov 7, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Overweight | $24 → $14 | $12.81 | +9.29% | 9 | Nov 7, 2025 | |
| SGMO Sangamo Therapeutics | Downgrades: Equal-Weight | $5 → $1 | $0.35 | +184.50% | 5 | Nov 7, 2025 | |
| PTCT PTC Therapeutics | Maintains: Equal-Weight | $46 → $68 | $64.54 | +5.36% | 17 | Nov 6, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Equal-Weight | $22 → $20 | $17.61 | +13.57% | 16 | Nov 5, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Equal-Weight | $408 → $414 | $448.62 | -7.72% | 18 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $9 | $6.68 | +34.73% | 8 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $9 | $9.66 | -6.83% | 11 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $460 → $527 | $308.05 | +71.08% | 9 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $95 | $69.68 | +36.34% | 14 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $80 | $54.09 | +47.90% | 16 | Oct 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $8 | $3.23 | +147.68% | 5 | Oct 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $7 → $17 | $21.85 | -22.20% | 10 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $37 | $7.81 | +373.75% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $56 | $46.43 | +20.61% | 17 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $25 → $21 | $23.95 | -12.32% | 10 | Aug 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $8.57 | +261.73% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $2.25 | +33.33% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $23.60 | -61.86% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $6.65 | +275.94% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $7.41 | +142.91% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $6.26 | +43.77% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $4.33 | +6,251.04% | 1 | Jan 6, 2017 |
Legend Biotech
Feb 4, 2026
Maintains: Overweight
Price Target: $90 → $80
Current: $17.09
Upside: +368.11%
Cytokinetics
Jan 28, 2026
Assumes: Overweight
Price Target: $87
Current: $60.02
Upside: +44.95%
Ultragenyx Pharmaceutical
Nov 24, 2025
Maintains: Overweight
Price Target: $81 → $50
Current: $18.50
Upside: +170.27%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Overweight
Price Target: $38 → $33
Current: $9.18
Upside: +259.48%
Moderna
Nov 7, 2025
Maintains: Equal-Weight
Price Target: $31 → $25
Current: $51.34
Upside: -51.31%
Intellia Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $24 → $14
Current: $12.81
Upside: +9.29%
Sangamo Therapeutics
Nov 7, 2025
Downgrades: Equal-Weight
Price Target: $5 → $1
Current: $0.35
Upside: +184.50%
PTC Therapeutics
Nov 6, 2025
Maintains: Equal-Weight
Price Target: $46 → $68
Current: $64.54
Upside: +5.36%
Sarepta Therapeutics
Nov 5, 2025
Maintains: Equal-Weight
Price Target: $22 → $20
Current: $17.61
Upside: +13.57%
Vertex Pharmaceuticals
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $408 → $414
Current: $448.62
Upside: -7.72%
Nov 4, 2025
Maintains: Overweight
Price Target: $10 → $9
Current: $6.68
Upside: +34.73%
Nov 4, 2025
Maintains: Equal-Weight
Price Target: $11 → $9
Current: $9.66
Upside: -6.83%
Oct 31, 2025
Maintains: Overweight
Price Target: $460 → $527
Current: $308.05
Upside: +71.08%
Oct 30, 2025
Maintains: Overweight
Price Target: $80 → $95
Current: $69.68
Upside: +36.34%
Oct 28, 2025
Maintains: Overweight
Price Target: $86 → $80
Current: $54.09
Upside: +47.90%
Oct 17, 2025
Maintains: Overweight
Price Target: $4 → $8
Current: $3.23
Upside: +147.68%
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $21.85
Upside: -22.20%
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $7.81
Upside: +373.75%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $46.43
Upside: +20.61%
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $23.95
Upside: -12.32%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $8.57
Upside: +261.73%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $2.25
Upside: +33.33%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $23.60
Upside: -61.86%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $6.65
Upside: +275.94%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $7.41
Upside: +142.91%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $6.26
Upside: +43.77%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $4.33
Upside: +6,251.04%